Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLH | Q9Y253 | 8/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | RECQL | P46063 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | MMP1 | P03956 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | APEX1 | P27695 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | NOX4 | Q9NPH5 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914456 | 0.86 | POLH (0.79) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL10728956 | 0.86 | POLH (1.00) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL7202826 | 0.86 | POLH (1.00) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL3757805 | 0.85 | POLH (0.74) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL14786208 | 0.84 | POLH (0.81) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL25304942 | 0.84 | POLH (1.00) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL30663836 | 0.84 | POLH (1.00) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL17620378 | 0.84 | POLH (0.89) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL28067122 | 0.84 | POLH (0.76) | POLHMEN1KMT2AKDM4EPOLB | |
| SCHEMBL25262255 | 0.83 | POLH (1.00) | POLHMEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143058-A1 | Pharmaceutical Compositions Comprising a Hydroxyethylquercetin Glucuronide | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-12 | — | — | US | claimed |
| EP-0289506-A4 | LIPOXYGENASE INHIBITORS | — | 1990-12-12 | — | — | EP | claimed |
| EP-0289506-A1 | LIPOXYGENASE INHIBITORS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-09 | — | — | EP | claimed |
| WO-1988003800-A1 | LIPOXYGENASE INHIBITORS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| US-20220143058-A1 | Pharmaceutical Compositions Comprising a Hydroxyethylquercetin Glucuronide | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-12 | — | — | US | disclosed |
| US-11304968-B2 | Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-19 | — | — | US | disclosed |
| EP-3860617-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A HYDROXYETHYLQUERCETIN GLUCURONIDE | Janssen Pharmaceutica N.V. (BE) | 2021-08-11 | — | — | EP | disclosed |
| US-20200155584-A1 | Pharmaceutical Compositions Comprising a Hydroxyethylquercetin Glucuronide | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-21 | — | — | US | disclosed |
| WO-2020070643-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A HYDROXYETHYLQUERCETIN GLUCURONIDE | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | WO | disclosed |
| US-20170105910-A1 | UV FILTER CAPSULE | BASF SE (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-1965639-B1 | INSECT REPELLENT MIXTURE | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | disclosed |
| EP-2170253-B1 | UV- FILTER CAPSULES | BASF SE (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2001089467-A1 | COMPOSITION CONTAINING AT LEAST ONE ARYL OXIME AND AT LEAST ONE ACTIVE SUBSTANCE FOR TREATING ACNE AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2001-11-29 | — | — | WO | disclosed |
| EP-1124980-A2 | METHOD FOR THE PRODUCTION OF QUERCETIN AND ISOQUERCETIN DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001054653-A1 | GALENIC FORMULATION | MERCK PATENT GMBH (DE) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000026399-A2 | METHOD FOR THE PRODUCTION OF QUERCETIN AND ISOQUERCETIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
| EP-0289506-A4 | LIPOXYGENASE INHIBITORS | — | 1990-12-12 | — | — | EP | disclosed |
| EP-0289506-A1 | LIPOXYGENASE INHIBITORS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-09 | — | — | EP | disclosed |
| WO-1988003800-A1 | LIPOXYGENASE INHIBITORS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| US-4708964-A | Lipoxygenase inhibitors | CHEMEX PHARMACEUTICALS (US) | 1987-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304968-B2 | Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide | COMT, UGT1A6, SLC6A2 | POLH 1043/4885MEN1 3746/4885KMT2A 3138/4885 |
| US-20220143058-A1 | Pharmaceutical Compositions Comprising a Hydroxyethylquercetin Glucuronide | COMT, UGT1A6, SLC6A2 | POLH 1043/4885MEN1 3746/4885KMT2A 3138/4885 |
| US-20170105910-A1 | UV FILTER CAPSULE | UROD, MITF, NISCH | POLH 1552/4885MEN1 1548/4885KMT2A 2903/4885 |
| US-20200155584-A1 | Pharmaceutical Compositions Comprising a Hydroxyethylquercetin Glucuronide | COMT, UGT1A6, SLC6A2 | POLH 1043/4885MEN1 3746/4885KMT2A 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.